Literatur

1. Adab N. Therapeutic Monitoring of antiepileptic drugs during pregnancy and the postpartum period. Is it useful? CNS Drugs 2006; 20: 791–800.
2. Allaire AD, Kuller JA. Psychotropic drugs in pregnancy and lactation. In: Yankowitz J, Niebyl JR (Eds.), Drug Therapy in Pregnancy. Philadelphia, PA, Lippincott, Williams & Wilkins, 2001; 127–230.
3. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592–606.
4. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM; National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. NEJM 2007; 356: 2684–2692.
5. Andermann E. Pregnancy and oxcarbazepine. Epilepsia 1994; 35(Suppl. 3): 26.
6. Artama M, Auvinen A, Raudaskoski T, Isojärvi I, Isojärvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005; 64: 1874–1878.
7. Ashton H. Psychotropic-drug prescribing for women. Br J Psychiatry 1991; 158 (Suppl.): 30–35.
8. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Bérard A, Koren G. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007; 29: 918–926.
9. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss, H-J, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G. The AGNP-TDM Expert Group Consensus Guidlines: Therpeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243–265.
10. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698–709.
11. Bergemann N, Paulus W. Antipsychotika in der Schwangerschaft. DNP – Der Neurologe & Psychiater 2009; 8: 34–42.
12. Bergemann N, Rommel F, Conca A. Therapeutisches Drug-Monitoring in der Schwangerschaft. Journal für Neurologie, Neurochirurgie und Psychiatrie 2009; 10: 38–40.
13. Bergemann N. Antidepressiva in der Schwangerschaft. Journal für Neurologie, Neurochirurgie und Psychiatrie 2009; 10: 41–47.
14. Brand SR, Brennan PA. Impact of Antenatal and postpartum maternal mental illness: how are the children? Clin Obstet Gynecol 2009; 52: 441–455.
15. Briggs G, Freeman S, Yaffe S. Drugs in Pregnancy and Lactation. Baltimore, MD, Williams and Williams, 1994.
16. Casper RC, Fleisher BE, Lee-Ancaja JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142: 402–408.
17. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579–587.
18. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192: 932–936.
19. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499–507 (Erratum in: JAMA 2006; 296: 170).
20. Cohen LS, Nonacs RM, Bailey JW, Viguera AC, Reminick AM, Altshuler LL, Stowe ZN, Faraone SV. Relapse of depression during pregnancy following antidepressant discontinuation: a preliminary prospective study. Arch Womens Ment Health 2004; 7: 217–221.
21. Cole JA, Ephross SA, Cosmatos, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 1075–1085.
22. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 474–484.
23. Cowe L, Lloyd DJ, Dawling S.Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J (Clin Res Ed) 1982; 284(6332):1837–1838.
24. Cunnington M, Ferber S, Quartey G, and the International Lamotrigine Pregnancy Registry Scientific Advisory Committee (2007) Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an International Observational Study. Epilepsia 2007; 48: 1207–1210.
25. de Moor RA, Mourad L, ter Haar J, Egberts AC. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneeskd 2003; 147: 1370–1372.
26. DeVane CL, Stowe ZN, Donovan JL, Newport DJ, Pennell PB, Ritchie JC Owens MJ, Wang JS. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol 2006; 20: 54–59.
27. Diav-Citrin O, Shechtman S, Weinbaum D, Arnon J, Di Gianantonio E, Clementi M, Ornoy A. Paroxetine and fluoxetine in pregnancy: controlled study. Reprod Toxicol 2005; 20: 459.
28. Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav-Citrin O, Kennedy D, Voyer Lavigne S, De Santis M, Einarson A. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006; 67: 1280–1284.
29. Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT; EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008; 71: 714–722.
30. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165: 749–752.
31. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323: 257–260.
32. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 2003; 64 (Suppl.): 9–14.
33. Freeman R. Limb deformities: possible association with drugs. Medical Journal of Australia 1972; 1: 606–607.
34. Garbis H, McElhatton PR. Psychotropic drugs. In: Schaefer C, Peters P, Miller RK (Eds.), Drugs During Pregnancy and Lactation. Treatment Options and Risk Assessment, 2nd edition. Amsterdam, Academic Press/Elsevier, 2007; 288–320.
35. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005; 28: 137–152.
36. GlaxoSmithKline. Bupropion Pregnancy Registry – Interim Report, 1 September 1997 through 28 February 2006.
37. Goldberg HL. Psychotropic drugs in pregnancy and lactation. Int J Psychiatry Med 1994; 2: 129–147.
38. Guclu S, Gol M, Dogan E, Savgili U. Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch Gynecol Obstet 2005; 272: 298–300.
39. Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27: 993–1002.
40. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clinical Pharmacology & Therapeutics 2002; 72: 184–191.
41. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73: 330–337.
42. Holmes LB, Wyszynski DF, Liebermann E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61: 673–678.
43. Hostetter A, Stowe ZN, Strader JR Jr, McLaughlin E, Llewellyn A. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11: 51–57.
44. Källén BA, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reproductive Toxicology 2006; 21: 221–222.
45. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79: 301–308.
46. Källén BA. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312–316.
47. Källén BA. The safety of antidepressant drugs during pregnancy. Expert Opin Drug Saf 2007; 6: 357–370.
48. Kinsella MT, Monk C. Impact of maternal stress, depression and anxiety on fetal neurobehavioral development. Clin Obstet Gynecol 2009; 52: 425–440.
49. Koren G. A new indication for therapeutic drug monitoring in the neonate. Ther Drug Monit 2006; 28: 1.
50. Krüger S. Psychopharmaka in Schwangerschaft und Stillzeit – Risiken und Möglichkeiten bei Frauen mit einer bipolaren affektiven Störung. Therapeutische Umschau 2009; 66: 475–484.
51. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Scheman AK, Cook L, Brochu J. Rieder M, Koren G. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. A prospective controlled multicenter study. JAMA 1998; 279: 609–610.
52. Lamberg L. Risks and benefits key to psychotropic use during pregnancy and postpartum period. JAMA 2005; 294: 1604–1608.
53. Lanczik M, Knoche M, Fritze J. Psychopharmakotherapie während Gravidität und Laktation. Teil 1: Gravidität. Nervenarzt 1998; 69: 1–9.
54. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007; 27: 607–613.
55. Loebstein R, Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit 2002; 24: 15–22.
56. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. NEJM 2007; 356: 2675–2683.
57. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50: 245–251.
58. McElhatton PR, Garbis HM, Eléfant E, Vial T, Bellemin B, Mastroiacovo P, Arnon J, Rodríguez-Pinilla E, Schaefer C, Pexieder T, Merlob P, Dal Verme S. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996; 10: 285–294.
59. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21: 157–171.
60. Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 2005; 21: 693–701.
61. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193–198.
62. Mortola JF. The use of psychotropic agents in pregnancy and lactation. Psychiatr Clin North Am 1989; 12: 69–87.
63. Moses-Kolko EL, Berga SL, Kalro B, Sit DKY, Wisner KL. Transdermal estradiol for postpartum depression: a promising treatment option. Clin Obstet Gynecol 2009; 52: 516–529.
64. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293: 2372–2383.
65. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JGW, Kulin N, Koren G. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258–262.
66. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159: 1889–1895.
67. Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure 2008; 17: 199–202.
68. O’Keane V, Marsh MS. Pregnancy Plus: Depression during pregnancy. BMJ 2007; 334: 1003-1005.
69. Pakalapati RK, Bolisetty S, Austin M-P, Oei J. Neonatal seizures from in utero venlafaxine exposure. J Paediatr Child Health 2006; 42: 737–739.
70. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246–2248.
71. Pedersen LH, Henriksen TB, Vestergaard N, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339: doi:10.1136/bmj.b3569.
72. Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, Newman M, Stowe ZN. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70: 2130–2136.
73. Rachelefsky GS, Flynt JW, Ebbin AJ. Possible teratogenicity of tricyclic antidepressants. Lancet 1972; 1: 838.
74. Rahman A, Bunn J, Lovel H, Creed F. Association between antenatal depression and low birthweight in a developing country. Acta Psychiatr Scand 2007; 115: 481–486.
75. Rahman A, Bunn J, Lovel H, Creed F. Maternal depression increases infant risk of diarrhoeal illness: a cohort study. Arch Dis Child 2007; 92: 24–28.
76. Rahman A, Iqbal Z, Bunn J, Lovel H, Harrington R. Impact of maternal depression on infant nutritional status and illness: a cohort study. Arch Gen Psychiatry 2004; 61: 946–952.
77. Rahman A, Iqbal Z, Harrington R. Life events, social support an depression in childbirth: perspectives from a rural community in the developing world. Psychol Med 2003; 33: 1161–1167.
78. Rayburn W, Wible-Kant J, Bledsoe J. Changing trends in drug use during pregnancy. Journal of Reproductive Medicine 1982; 27: 569–575.
79. Robert E. Treating depression in pregnancy. NEJM 1996; 335: 1056–1058.
80. Ruchkin V, Martin A. SSRIs and the developing brain. Lancet 2005; 365(9458): 451–453.
81. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365(9458): 482–487.
82. Schaefer C, Spielmann H, Vetter K. Arzneiverordnung in Schwangerschaft und Stillzeit, 7. Auflage. München und Jena, Urban & Fischer, 2007.
83. Schaefer C. Psychotropic drugs. In: Schaefer C, Peters P, Miller RK (Eds.), Drugs During Pregnancy and Lactation. Treatment Options and Risk Assessment, 2nd edition. Amsterdam, Academic Press/Elsevier, 2007; 708–737.
84. Schardein JL. Chemically Induced Birth Defects, 3rd edition. New York NY, Marcel Dekker, 2000.
85. Schimmell MS, Katz EZ, Shaag Y, Pastuszak A, Koren G. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991; 29: 479-484.
86. Sokolover N, Merlob P, Klinger G. Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. Can J Clin Pharmacol 2008; 15: 188–190.
87. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007; 164: 1206–1213.
88. Vajda FJ, Hitchcock A, Graham J, Solinas C, O'Brien TJ, Lander CM, Eadie MJ. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol 2006, 13: 645–654.
89. Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, Zurick A, Cohen LS. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164: 1817–1824 .
90. Wadhawa PD, Glynn L, Hobel CJ, Garite TJ, Porto M, Chicz-DeMet A, Wiglesworth AK, Sandman CA. Behavioral perinatology: biobehavioral processes in human fetal development. Regul Pept 2002; 108: 149–157.
91. Warner JP. Evidence-based psychopharmacology 3. Assessing evidence of harm: what are the teratogenic effects of lithium carbonate? Psychopharmacol 2000; 14: 77–80.
92. Weinberg MK, Tronick EZ. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry 1998; 59: 53–61 .
93. Weinstein MR, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 1975; 132: 529–531.
94. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009. 84: 23–27.
95. Wiesner KL, Gelenberg AJ, Leonard H, Zarin D, Johanson R, Frank E. Pharmacological treatment of depression during pregnancy. JAMA 1999; 282: 1264–1269.
96. Yacobi S, Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr J Psychiatry Relat Sci 2008; 45: 95–106.
97. Yankowitz J, Niebyl JR. Folic acid supplementation for prevention of birth defects. In: Yankowitz J, Niebyl JR (eds.), Drug therapy in pregnancy, 3rd edition. Philadelphia: Lippincott Williams & Wilkins, 2001; 187–193.
98. Zegers B, Andriessen P. Maternal lithium therapy and neonatal morbidity. Eur J Pediatr 2003; 162: 348-349.
99. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113: 368–375.